IM7 Stock Overview
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IM7 from our risk checks.
Inari Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.00 |
| 52 Week High | US$59.50 |
| 52 Week Low | US$34.20 |
| Beta | 1.02 |
| 11 Month Change | 2.22% |
| 3 Month Change | 16.75% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 12.2% | -0.2% | -0.5% |
| 1Y | n/a | -0.1% | 1.6% |
Return vs Industry: Insufficient data to determine how IM7 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how IM7 performed against the German Market.
Price Volatility
| IM7 volatility | |
|---|---|
| IM7 Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: IM7's share price has been volatile over the past 3 months.
Volatility Over Time: IM7's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,300 | Drew Hykes | www.inarimedical.com |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons.
Inari Medical, Inc. Fundamentals Summary
| IM7 fundamental statistics | |
|---|---|
| Market cap | €2.69b |
| Earnings (TTM) | -€21.95m |
| Revenue (TTM) | €483.85m |
5.6x
P/S Ratio-122.6x
P/E RatioIs IM7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM7 income statement (TTM) | |
|---|---|
| Revenue | US$520.66m |
| Cost of Revenue | US$64.22m |
| Gross Profit | US$456.44m |
| Other Expenses | US$480.06m |
| Earnings | -US$23.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 87.67% |
| Net Profit Margin | -4.54% |
| Debt/Equity Ratio | 0% |
How did IM7 perform over the long term?
See historical performance and comparison